Additionally, preclinical and clinical studies show that T cells expressing CD28 CARs are initially faster to proliferate and kill tumor cells, but suffer from reduced long-term engraftment and heightened exhaustion after prolonged activation(8–12). This evidence concerns the gene CD28 and neoplasm.